Irhythm Technologies Inc is a medical technology company that specializes in the development and commercialization of innovative solutions for cardiac monitoring and arrhythmia detection
The company's flagship product is a wearable ECG monitoring device that allows for continuous heart rhythm assessment, enabling healthcare providers to make more informed decisions regarding patient care. Irhythm aims to improve patient outcomes through its advanced technology, which streamlines the diagnosis and management of various heart conditions, thus enhancing the overall healthcare experience for both patients and providers.
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom (NASDAQDXCM).
Medical technology company iRhythm Technologies (NASDAQIRTC) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24% year on year to $164.3 million. The company expects the full year’s revenue to be around $680 million, close to analysts’ estimates. Its non-GAAP profit of $0.01 per share was significantly above analysts’ consensus estimates.
Medical technology company iRhythm Technologies (NASDAQIRTC)
will be announcing earnings results tomorrow afternoon. Here’s what investors should know.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
FDA approves iRhythm's 510(k) submission for Zio AT device. A second approval may come soon, enhancing the company's mobile cardiac telemetry services.
